Adjuvant Global Health Technology Fund, L.P.

Average Profitability
<0.0001%
Insider Buys Quantity
1
Insider Buys Sum
$2.5M
Insider Sells Quantity
10
Insider Sells Sum
$3.98M

Insider Activity of Adjuvant Global Health Technology Fund, L.P.

According to the SEC Form 4 filings, Adjuvant Global Health Technology Fund, L.P., being in a position of

  1. 10 percent owner at AN2 Therapeutics, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 100000 shares for $1.97M,
    over all time since 2022-03-29, has bought 166666 shares for $2.5M, and sold 223880 shares for $3.98M.

The largest purchase of all time was on 2022-03-29 and amounted to 166666 shares of AN2 Therapeutics, Inc. for $2.5M.

The largest sale of all time was on 2024-01-16 and amounted to 100000 shares of AN2 Therapeutics, Inc. for $1.97M.

Biography of Adjuvant Global Health Technology Fund, L.P.

No biography is available at this moment.

2024-01-16SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
100,000
3.9381%
$19.65$1.97M-89.49%
2023-11-14SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
1,810
0.0586%
$16.15$29,224-84.06%
2023-10-02SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
5,672
0.1827%
$16.07$91,149-80.98%
2023-09-29SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
99,101
3.2333%
$16.28$1.61M-81.53%
2023-09-28SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
8,516
0.2749%
$16.11$137,193-81.33%
2023-09-27SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
841
0.0271%
$16.07$13,515-81.17%
2023-09-13SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
400
0.0128%
$16.00$6,400-79.54%
2023-09-07SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
3,378
0.1087%
$16.05$54,217-79.87%
2023-09-06SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
3,762
0.1208%
$16.02$60,267-80.19%
2023-08-23SaleAN2 Therapeutics, Inc.
ANTX
10 percent owner
400
0.0128%
$16.00$6,400-77.74%
2022-03-29PurchaseAN2 Therapeutics, Inc.
ANTX
10 percent owner
166,666
5.0102%
$15.00$2.5M-24.72%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.